Bolt Biotherapeutics Income Statement (2020-2026) | BOLT

Income Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
0.75M0.51M0.81M1.39M2.11M1.41M1.83M1.43M2.53M2.09M5.27M1.27M1.14M1.22M1.80M2.17M2.50M0.03M
Operating items
Research & Development (Quarter)
19.71M19.34M22.48M18.39M18.92M18.97M16.84M14.62M15.64M14.95M16.32M16.53M15.43M13.79M11.72M9.51M7.50M6.54M4.99M4.83M
Selling, General & Administrative (Quarter)
4.05M4.94M5.10M6.30M5.53M5.49M5.61M5.62M5.62M5.76M5.53M5.84M4.87M3.80M3.95M3.83M3.52M3.34M3.12M2.80M
Restructuring Costs (Quarter)
3.56M-0.22M1.48M
Other Operating Expenses (Quarter)
1.47M
Operating Expenses (Quarter)
23.76M24.28M27.58M24.69M24.45M24.46M22.45M20.24M21.27M20.71M21.86M22.37M23.87M17.58M16.92M13.34M11.01M9.87M9.59M7.63M
Operating Income (Quarter)
-23.76M-23.53M-27.07M-23.88M-23.06M-22.35M-21.04M-18.41M-19.83M-18.18M-19.77M-17.09M-22.60M-16.44M-16.92M-12.12M-9.21M-7.70M-7.08M-7.60M
EBIT (Quarter)
-23.76M-23.53M-27.07M-23.88M-23.06M-22.35M-21.04M-18.41M-19.83M-18.18M-19.77M-17.09M-22.60M-16.44M-16.92M-12.12M-9.21M-7.70M-7.08M-7.60M
Non-operating items
Interest & Investment Income (Quarter)
0.18M0.13M-0.08M0.20M0.40M0.59M1.04M1.44M1.77M1.93M1.86M1.61M1.40M1.27M0.98M1.05M0.60M0.48M0.37M0.28M
Non Operating Income (Quarter)
0.18M0.13M-0.08M0.20M0.40M0.59M1.04M1.44M1.77M1.93M1.86M6.28M1.40M1.27M0.98M1.07M0.65M0.56M0.45M0.36M
Net income details
EBT (Quarter)
-23.59M-23.39M-27.16M-23.68M-22.66M-21.76M-20.00M-16.98M-18.06M-16.26M-17.90M-15.49M-21.20M-15.18M-15.94M-11.06M-8.61M-7.23M-6.72M-7.33M
Profit After Tax (Quarter)
-23.59M-23.39M-27.16M-23.68M-22.66M-21.76M-20.00M-16.98M-18.06M-16.26M-17.90M-10.81M-21.20M-15.18M-15.94M-11.04M-8.56M-7.14M-6.63M-7.24M
Income from Continuing Operations (Quarter)
-23.59M-23.39M-27.16M-23.68M-22.66M-21.76M-20.00M-16.98M-18.06M-16.26M-17.90M-15.49M-21.20M-15.18M-15.94M-11.06M-8.61M-7.23M-6.72M-7.33M
Consolidated Net Income (Quarter)
-23.59M-23.39M-27.16M-23.68M-22.66M-21.76M-20.00M-16.98M-18.06M-16.26M-17.90M-15.49M-21.20M-15.18M-15.94M-11.06M-8.61M-7.23M-6.72M-7.33M
Income towards Parent Company (Quarter)
-23.59M-23.39M-27.16M-23.68M-22.66M-21.76M-20.00M-16.98M-18.06M-16.26M-17.90M-15.49M-21.20M-15.18M-15.94M-11.06M-8.61M-7.23M-6.72M-7.33M
Net Income towards Common Stockholders (Quarter)
-23.59M-23.39M-27.16M-23.68M-22.66M-21.76M-20.00M-16.98M-18.06M-16.26M-17.90M-15.49M-21.20M-15.18M-15.94M-11.06M-8.61M-7.23M-6.72M-7.33M
Additional items
EPS (Basic) (Quarter)
-0.64-0.63-0.73-0.64-0.61-0.58-0.53-0.45-0.48-0.43-0.47-0.28-11.12-7.93-8.33-5.76-4.46-3.72-3.91-4.31
EPS (Weighted Average and Diluted) (Quarter)
-0.63-0.73-0.64-0.61-0.58-0.53-0.45-0.48-0.43-0.47-0.28-11.12-7.93-8.33-5.76-4.46-3.72-3.91-4.31
Shares Outstanding (Weighted Average) (Quarter)
36.60M37.21M33.20M37.13M37.21M37.45M37.36M37.68M37.72M37.77M37.81M38.07M1.91M1.91M1.91M1.92M1.92M1.92M1.87M1.68M
Shares Outstanding (Diluted Average) (Quarter)
37.21M33.20M37.13M37.29M37.29M37.36M37.68M37.75M37.77M37.81M38.07M1.91M1.91M1.91M1.92M1.92M1.92M1.87M1.68M
EBITDA (Quarter)
-23.54M-23.41M-27.44M-24.75M-23.07M-21.66M-19.21M-16.30M-18.05M-16.20M-17.69M-10.88M-21.20M-14.93M-16.04M-11.10M-8.61M-7.15M-6.64M-7.23M
Shares Outstanding (Quarter)
37.19M37.25M37.40M37.47M37.64M37.66M37.80M37.81M37.95M37.97M1.91M1.91M1.91M1.91M1.92M1.92M1.92M1.92M1.92M1.92M